Srividya B. Balachander

机构：Bristol-Myers Squibb (Germany), Bristol-Myers Squibb (Belgium) · ORCID：0000-0002-4653-0432

发表论文 41 篇 · 总被引 230 次 · h-index 5

代表论文

Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models (2024 · Blood Advances · 被引 10)
Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C (2026 · Nature Communications · 被引 3)
Optimization of α‑Fluoro, β‑Heteroaryl Acrylamide Warheads for KRASG12C Active-State Inhibition (2026 · Figshare)
Optimization of α‑Fluoro, β‑Heteroaryl Acrylamide Warheads for KRASG12C Active-State Inhibition (2026 · Figshare)
Optimization of α-Fluoro, β-Heteroaryl Acrylamide Warheads for KRAS G12C Active-State Inhibition (2026 · Journal of Medicinal Chemistry)
Abstract 6150: AZD0466, a dual BCL-2/XL targeting nanomedicine, is active in small cell lung cancer models (2023 · Cancer Research)